Limits...
Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group.

De Pas T, Bodei L, Pelosi G, De Braud F, Villa G, Capanna R, Paganelli G, Italian Sarcoma Gro - Br. J. Cancer (2003)

Bottom Line: The management of aggressive fibromatosis (AF) is problematic, and few options are available to patients unsuitable for surgery and resistant to external-beam radiation therapy (EBRT).We report on two patients with fast-growing recurrences of AF resistant to EBRT who obtained protracted clinical benefits with (90)Y-DOTATOC. (90)Y-DOTATOC should be further investigated in this setting.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Oncology, European of Oncology, Via Ripamonti, Milan, Italy. tommaso.de-pas@ieo.it

ABSTRACT
The management of aggressive fibromatosis (AF) is problematic, and few options are available to patients unsuitable for surgery and resistant to external-beam radiation therapy (EBRT). We report on two patients with fast-growing recurrences of AF resistant to EBRT who obtained protracted clinical benefits with (90)Y-DOTATOC. (90)Y-DOTATOC should be further investigated in this setting.

Show MeSH

Related in: MedlinePlus

The patient had a local relapse of right-thigh aggressive fibromatosis: a scintigraphy with 111In-labelled octreotide (OctreoScan) revealed tumour uptake of the radiopeptide (arrow).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376350&req=5

fig1: The patient had a local relapse of right-thigh aggressive fibromatosis: a scintigraphy with 111In-labelled octreotide (OctreoScan) revealed tumour uptake of the radiopeptide (arrow).

Mentions: The first patient, a 30-year-old woman, had a local relapse of right-thigh AF. Nine months after the primary tumour had been radically removed, she underwent further surgery for a local relapse; however, during subsequent adjuvant external-beam radiotherapy the disease again recurred and grew rapidly. The patient received i.v., 90Y-DOTATOC in five cycles over 14 months, cumulative activity 10.6 GBq. There was a partial response on MRI according to WHO criteria after the first cycle (2.22 GBq) which has lasted for more than 37 months (Figures 1Figure 1


Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group.

De Pas T, Bodei L, Pelosi G, De Braud F, Villa G, Capanna R, Paganelli G, Italian Sarcoma Gro - Br. J. Cancer (2003)

The patient had a local relapse of right-thigh aggressive fibromatosis: a scintigraphy with 111In-labelled octreotide (OctreoScan) revealed tumour uptake of the radiopeptide (arrow).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376350&req=5

fig1: The patient had a local relapse of right-thigh aggressive fibromatosis: a scintigraphy with 111In-labelled octreotide (OctreoScan) revealed tumour uptake of the radiopeptide (arrow).
Mentions: The first patient, a 30-year-old woman, had a local relapse of right-thigh AF. Nine months after the primary tumour had been radically removed, she underwent further surgery for a local relapse; however, during subsequent adjuvant external-beam radiotherapy the disease again recurred and grew rapidly. The patient received i.v., 90Y-DOTATOC in five cycles over 14 months, cumulative activity 10.6 GBq. There was a partial response on MRI according to WHO criteria after the first cycle (2.22 GBq) which has lasted for more than 37 months (Figures 1Figure 1

Bottom Line: The management of aggressive fibromatosis (AF) is problematic, and few options are available to patients unsuitable for surgery and resistant to external-beam radiation therapy (EBRT).We report on two patients with fast-growing recurrences of AF resistant to EBRT who obtained protracted clinical benefits with (90)Y-DOTATOC. (90)Y-DOTATOC should be further investigated in this setting.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Oncology, European of Oncology, Via Ripamonti, Milan, Italy. tommaso.de-pas@ieo.it

ABSTRACT
The management of aggressive fibromatosis (AF) is problematic, and few options are available to patients unsuitable for surgery and resistant to external-beam radiation therapy (EBRT). We report on two patients with fast-growing recurrences of AF resistant to EBRT who obtained protracted clinical benefits with (90)Y-DOTATOC. (90)Y-DOTATOC should be further investigated in this setting.

Show MeSH
Related in: MedlinePlus